Gene editing of B cells to combat HIV
In Vivo Gene Editing of B cells with NICE-AAV Vectors
This study is exploring a new gene therapy that could help people with HIV by using special tools to target their immune cells, aiming to provide a lasting solution that might eliminate the virus and reduce the need for ongoing medication.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Fred Hutchinson Cancer Center NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project ID | NIH-10984484 on NIH RePORTER |
What this research studies
This research focuses on developing innovative gene therapies to achieve a cure or stable remission for HIV without the need for ongoing antiretroviral therapy. The approach utilizes engineered adeno-associated virus (AAV) vectors that specifically target B cells and deliver CRISPR-Cas9 gene editing tools. By overcoming challenges such as the transient nature of antibody therapies and immune responses to gene therapy vectors, this research aims to provide a long-lasting solution to HIV treatment. Patients may benefit from a more effective and durable therapy that could potentially eliminate the virus from their systems.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals living with HIV who are seeking alternative treatment options beyond traditional antiretroviral therapy.
Not a fit: Patients who are not infected with HIV or those who have advanced AIDS may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a groundbreaking treatment that allows HIV patients to achieve long-term remission without continuous medication.
How similar studies have performed: Previous research has shown promise in using gene therapies for HIV, but this specific approach utilizing B cell-targeted AAV vectors is novel and untested.
Where this research is happening
Seattle, United States
- Fred Hutchinson Cancer Center — Seattle, United States (Active)
Researchers
- Principal investigator: Peterson, Christopher W — Fred Hutchinson Cancer Center
- Study coordinator: Peterson, Christopher W
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.